The National Institutes of Health said Thursday that it stopped enrollment in two clinical trials evaluating experimental COVID-19 therapies after discovering they likely do not provide a benefit to hospitalized patients. The treatment candidates are GlaxoSmithKline /zigman2/quotes/209463850/composite GSK +1.16% and Vir Biotechnology Inc.'s /zigman2/quotes/214486077/composite VIR +3.27% monoclonal antibody therapy and the privately held Brii Biosciences Inc.'s monoclonal antibody cocktail. Vir told investorson Thursday that the NIH had notified the company about stopping the trial. There were no safety concerns for either therapy. Over the past year, GSK's stock is down 20.0% and shares of Vir tumbled 9.4%, while the broader S&P 500 /zigman2/quotes/210599714/realtime SPX +0.74% has rallied 20.4%.